若生智能
Drug Database
DI

diphtheria + acellular pertussis + tetanus vaccine

✓ Approved

China National Pharmaceutical · 疫苗 · 疫苗

什么是 diphtheria + acellular pertussis + tetanus vaccine？

diphtheria + acellular pertussis + tetanus vaccine 是一种疫苗，由China National Pharmaceutical研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)。

药物档案

公司China National Pharmaceutical
药物类别疫苗
给药途径Injectable (Others)
状态Approved
来源： ClinicalTrials.gov, China National Pharmaceutical

治疗适应症

diphtheria + acellular pertussis + tetanus vaccine 针对 3 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsDiphtheria✓ Approved
Infections and infestationsPertussis✓ Approved
Infections and infestationsTetanus✓ Approved

相关研究文献

PubMedFrontiers in pediatrics2026-08-04

Clinical and laboratory characteristics of critical Bordetella pertussis in hospitalized infants in the Southwest region of Saudi Arabia.

Asseri Ali Alsuheel AA, Alshehri Norah N, AlHelali Ibrahim I, Al-Benhassan Ibrahim I et al.

Critical pertussis remains a critical health concern in infants and is characterized by severe leukocytosis, respiratory failure, and multisystem involvement. Despite global vaccination efforts, outbreaks continue to occur, particularly among unvaccinated or partially vaccinated infants. This study aimed to describe the clinical, laboratory, and management characteristics of critically ill infants with critical Bordetella pertussis in the southwest region of Saudi Arabia, with a focus on comparing survival and non-survival outcomes. A retrospective cohort study was conducted involving 70 infants hospitalized for severe pertussis between January 2024 and April 2025. Data collected included demographic details, presenting symptoms, comorbidities, vital signs, laboratory parameters [e.g., white blood cell (WBC) count, inflammatory markers, liver enzymes], treatments received (e.g., macrolides, exchange transfusions, leukoreduction therapies), and clinical outcomes. Statistical analyses included descriptive statistics and comparative tests (t-test, Mann-Whitney U test, chi-squared test). Among the 70 infants, the median age was 3 months, with 46.4% of the infants aged < 3 months. Non-survivors (n = 4) exhibited significantly higher leukocyte counts (median WBC, 87.5 × 103/µL) and neutrophil levels, profound hypoxemia, and higher inflammatory marker levels (C-reactive protein, erythrocyte sedimentation rate) than survivors. They also more frequently had coexisting conditions, such as congenital heart disease and genetic disorders. Clinical features, such as apnea, seizures, and hypoxemia, were strongly associated with death. All fatal cases involved severe pulmonary hypertension, which necessitated aggressive interventions, including exchange transfusions, inhaled nitric oxide, and inotropes. The laboratory findings of non-survivors showed marked leukocytosis, elevated liver enzyme levels, hyponatremia, and thrombocytopenia. Therapeutic efforts, including leukoreduction and advanced supportive measures, were more prevalent in non-survivors than in survivors but were insufficient to alter outcomes. Critical pertussis primarily affects unimmunized infants <3 months and is associated with severe illness and a notable fatality rate despite intensive care. Strengthening maternal and infant immunization, along with early risk identification and prompt intervention, is essential. Further research and public health efforts are needed to reduce disease burden.

PMID 42548733
阅读全文 →
PubMedAnatomy & cell biology2026-08-04

Acellular lung matrix scaffold coated by fibronectin enhances hepatic differentiation of adipose-derived mesenchymal stem cells.

Nejad Darioush Bijan DB, Azandeh Seyyed Saeed SS, Bayati Vahid V, Orazizadeh Mahmoud M et al.

End-stage liver disease is a multifactorial disorder and leading cause of death. The development of effective tissue models has been a focus of research for treating liver disease. This study investigated the use of acellular lung matrix (ALM) and fibronectin (FN) to culture adipose-derived mesenchymal stem cells (ADMSCs) and promote their differentiation into hepatic-like cells. In this experimental study, sodium deoxycholate and NaCl were used to decellularize the lungs, and scaffolds were characterized by histology, scanning electron microscopy, and DNA quantification. ADMSCs were differentiated into hepatocyte-like cells using a two-step protocol under three conditions: in two-dimensional culture, on ALM scaffolds, and on FN-coated ALM scaffolds. Hepatic differentiation was confirmed by RT-PCR for specific genes (alpha-fetoprotein [AFP], albumin [ALB], cytokeratin-18 [CK-18]), ALB and urea levels were measured using specific commercial kits. The main extracellular matrix components (collagen and glycosaminoglycans) were preserved, and residual DNA was minimal (P<0.001), indicating effective decellularization. ADMSCs cultured on FN-coated ALM exhibited significantly higher expression of hepatic markers (AFP, P<0.01; ALB, P<0.01; CK-18, P<0.01). Functional assay confirmed higher ALB and urea production (P<0.05), while MTT assay demonstrated that the scaffold was non-cytotoxic. Collectively, these results demonstrate that FN-coated ALM holds considerable potential for facilitating the hepatic differentiation of ADMSCs under the applied induction conditions.

PMID 42547247
阅读全文 →
PubMedCureus2026-08-04

Patient Profile and Referral Pattern in a Tertiary Care Infectious Disease Hospital of Bangladesh: A Cross-Sectional Study.

Hasan Mohammad Jahid MJ, Rabbi Mohammad Mehedi Hasan MMH, Chowdhury Abdullah Al Tahsin AAT, Hasan Zubayer Z et al.

Introduction Infectious diseases are attributable to a large proportion of the disease burden in Bangladesh. The disease profile and referral pattern of these patients are important for understanding healthcare utilization and improving system efficiency in resource-limited settings. Hence, the objective of the present study was to assess the patient profiles and referral patterns at the Infectious Diseases Hospital (IDH), Dhaka, Bangladesh. Methods This cross-sectional study was conducted at IDH, Mohakhali, Bangladesh. Using a systematic sampling, a total of 308 patients (161 outpatients and 147 inpatients) were recruited. Data regarding patients' sociodemographic, diagnosis, and referral were collected through face-to-face interviews using a semi-structured questionnaire. Descriptive statistics were used to represent the findings. Results The mean age of the patients was 31.5 years (standard deviation, SD 16), with 66% (n=204) being male subjects and 56% (n=172) residing in urban areas. Among outpatients, 93% (n=150) presented with animal bites or scratches, while inpatients presented with more severe conditions, including contagious viral infections (28.6%, n=42), tetanus (26%, n=38), and acquired immune deficiency syndrome (AIDS) (25%, n=37). Overall, 39.6% (n=122) of patients were institutionally referred, with higher referral rates among inpatients (68%, n=100) than outpatients (13.7%, n=22). Primary care facilities accounted for 33% (n=40) of institutional referrals. Inadequate treatment facilities (54%, n=54), shortages of specialist physicians and other staff (41%, n=41), insufficient diagnostic facilities (33%, n=33), and inadequate vaccine or medicine supply (22%, n=22) were the most common reasons for both institutional and self-referral. Conclusion A substantial number of patients were self-referred at IDH. Strengthened primary care infrastructure and referral systems would optimize tertiary care utilization and improve healthcare access in Bangladesh.

PMID 42549389
阅读全文 →
PubMedThe Lancet. Infectious diseases2026-08-04

Efficacy, immunogenicity, and safety of the 9-valent human papillomavirus vaccine in males aged 16-26 years in Japan: a randomised, double-blind, placebo-controlled trial.

Hisamoto Koji K, Yamanaka Masaki M, Nomura Masayasu M, Kanno Nobufumi N et al.

Efficacy of the nine-valent human papillomavirus (9vHPV; HPV6, 11, 16, 18, 31, 33, 45, 52, and 58) vaccine was shown in females and inferred for males through immunobridging. We evaluated the efficacy of the 9vHPV vaccine in males aged 16-26 years. This randomised, double-blind, placebo-controlled, efficacy, immunogenicity, and safety phase 3 trial was conducted at 22 clinical research, hospital, medical, or treatment sites in Japan, with masking of investigators, sponsor personnel, and participants. Healthy males aged 16-26 years with no history of human papillomavirus (HPV)-related lesions and no previous HPV vaccination were randomly assigned (1:1) centrally, using permutated blocks (block sizes of four), to receive three intramuscular injections of the 9vHPV vaccine or placebo (saline) at day 1, month 2, and month 6. The primary and secondary efficacy endpoints were the combined incidences of 6-month anogenital persistent infection related to HPV6, 11, 16, and 18 and HPV31, 33, 45, 52, and 58. Anogenital swabs and external genital tissue samples were tested for the presence of HPV DNA. Tissue samples were adjudicated for histopathology diagnosis. The primary and secondary efficacy evaluations were tested for superiority with a margin of 0% in the per-protocol population. Another secondary endpoint was antibody responses to each vaccine-targeted HPV type at month 7; immunogenicity analyses were conducted in the per-protocol immunogenicity population. Safety was assessed in participants who received at least one dose of vaccine or placebo. This study is registered with ClinicalTrials.gov (NCT04635423) and is completed. Between Nov 30, 2020, and Dec 25, 2021, 1059 participants were enrolled and randomly assigned to receive the 9vHPV vaccine (n=529) or placebo (n=530). Vaccine efficacy for the primary and secondary endpoints was 89·3% (95% CI 55·4-98·2; p=0·0002) and 63·5% (2·7-86·0; p=0·023), respectively, in the initial efficacy analysis based on a visit cutoff date of Dec 29, 2023, and 91·6% (67·7-98·6) and 72·9% (38·7-89·3) in the end-of-study efficacy analysis based on a visit cutoff date of July 16, 2024. Seroconversion rates were greater than 98% for each vaccine-targeted HPV type. Injection-site adverse events were reported in 370 (70%) of 529 9vHPV vaccine recipients and 162 (31%) of 530 placebo recipients, and vaccine-related systemic adverse events in 58 (11%) vaccine recipients and 52 (10%) placebo recipients; most cases were mild or moderate. No deaths, vaccine-related serious adverse events, or discontinuations due to adverse events were reported. The 9vHPV vaccine prevents anogenital persistent infection related to vaccine-targeted HPV types in males and has an acceptable safety profile. These findings support the use of the 9vHPV vaccine in males to prevent HPV-related anogenital diseases. Merck Sharp & Dohme. For the Japanese translation of the abstract see Supplementary Material section.

PMID 42546724
阅读全文 →
PubMedClinics in geriatric medicine2026-08-04

Vaccine-Preventable Diseases in Older Adults.

Al-Jabri Maha M, Rosero Christian C, Saade Elie A EA

Older adults are at an increased risk of vaccine-preventable diseases partly because of physiologic changes in the immune and other body systems related to age and/or accumulating comorbidities that increase the vulnerability to infections and decrease the response to vaccines. Strategies to improve the response to vaccines include using a higher antigenic dose (such as in the high-dose inactivated influenza vaccines) as well as adding adjuvants (such as MF59 in the adjuvanted inactivated influenza vaccine).

PMID 42547175
阅读全文 →
PubMedInfection and immunity2026-08-04

A multivalent subunit vaccine augments pre-existing immunity to protect against T3SS-positive Pseudomonas aeruginosa but reveals immunological interference against ExlA-positive strains.

Howlader Debaki R DR, Das Sayan S, Biswas Satabdi S, Dietz Zackary K ZK et al.

Pseudomonas aeruginosa (Pa) is a ubiquitous, opportunistic nosocomial pathogen that poses a significant threat due to its innate and acquired multidrug resistance. Novel vaccine strategies are urgently needed for vulnerable populations, many of which harbor pre-existing immunity from prior encounters with Pa. Here, we evaluated a multivalent subunit vaccine combining type III secretion system (T3SS) antigens and exolysin A (ExlA) in a nanoemulsion formulation using a clinically relevant murine pulmonary pre-exposure model. This approach allowed us to determine whether vaccination could overcome the limitations of the host's initial, ineffective immune response. Vaccination fundamentally transforms suboptimal baseline memory into a potent, multi-faceted Th1/Th17-polarized response. This globally transformed signature was characterized by significantly enhanced antigen-specific IFN-γ and IL-17A production, both locally and systematically in the lung, with exceptionally large biological effect sizes (Cohen's d values reaching 21.35). By utilizing log10 transformation to accurately reflect pathogen growth kinetics, we demonstrated that this vaccine-augmented immunity conferred statistically significant protection following heterologous challenge. In the twice-exposed cohort, vaccination promoted superior bacterial clearance of the T3SS-positive strain, though clearance of the ExlA-positive strain was not enhanced, potentially due to immunological interference from pre-existing T3SS memory. In the thrice-exposed cohort, a functional protective threshold was observed, where high levels of natural immunity matched the vaccine-induced clearance levels. Our findings established that our vaccine formulation can effectively boost and redirect pre-existing immunity, offering a promising approach to overcome the limitations of natural exposure and protect at-risk individuals from diverse Pa infections.

PMID 42550059
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多diphtheria + acellular pertussis + tetanus vaccine